This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Christ, E. R. Articles by Russell-Jones, D. L. Search for Related Content PubMed PubMed Citation Articles by Christ, E. R. Articles by Russell-Jones, D. L.

Effects of Growth Hormone (GH) Replacement Therapy on Very Low Density Lipoprotein Apolipoprotein B100 Kinetics in Patients with Adult GH Deficiency: A Stable Isotope Study¹

Departments of Medicine (E.R.C., M.H.C., E.A., A.M.A., M.A.B., P.H.S., D.L.R.-J.) and Chemical Pathology (P.J.L., A.S.W.), St. Thomas’ Hospital, and the Medical Research Council Lipoprotein Team, Hammersmith Hospital, Clinical Sciences Center (R.P.N.), London, United Kingdom SE1 7EH

Address all correspondence and requests for reprints to: Dr. E. Christ, Department of Diabetology and Endocrinology, 44th floor, bâtiment de liaison, Hôpital Universitaire de Genève, CH 1211 Genèva 14, Switzerland. E-mail: EmanuellChrist{at}hcuge.ch

Patients with adult GH deficiency are often dyslipidemic and may have an increased risk of cardiovascular disease. The secretion and clearance of very low density lipoprotein apolipoprotein B 100 (VLDL apoB) are important determinants of plasma lipid concentrations. This study examined the effect of GH replacement therapy on VLDL apoB metabolism using a stable isotope turnover technique. VLDL apoB kinetics were determined in 14 adult patients with GH deficiency before and after 3 months GH or placebo treatment in a randomized double blind, placebo-controlled study using a primed constant [1-¹³C]leucine infusion. VLDL apoB enrichment was determined by gas chromatography-mass spectrometry. GH replacement therapy increased plasma insulin-like growth factor I concentrations 2.9 ± 0.5-fold (P < 0.001), fasting insulin concentrations 1.8 ± 0.6-fold (P < 0.04), and hemoglobin A_1C from 5.0 ± 0.2% to 5.3 ± 0.2% (mean ± SEM; P < 0.001). It decreased fat mass by 3.4 ± 1.3 kg (P < 0.05) and increased lean body mass by 3.5 ± 0.8 kg (P < 0.01). The total cholesterol concentration (P < 0.02), the low density lipoprotein cholesterol concentration (P < 0.02), and the VLDL cholesterol/VLDL apoB ratio (P < 0.005) decreased. GH therapy did not significantly change the VLDL apoB pool size, but increased the VLDL apoB secretion rate from 9.2 ± 2.0 to 25.9 ± 10.3 mg/kg·day (P < 0.01) and the MCR from 11.5 ± 2.7 to 20.3 ± 3.2 mL/min (P < 0.03). No significant changes were observed in the placebo group. This study suggests that GH replacement therapy improves lipid profile by increasing the removal of VLDL apoB. Although GH therapy stimulates VLDL apoB secretion, this is offset by the increase in the VLDL apoB clearance rate, which we postulate is due to its effects in up-regulating low density lipoprotein receptors and modifying VLDL composition.

This article has been cited by other articles:

				C. Beauregard, A. L. Utz, A. E. Schaub, L. Nachtigall, B. M. K. Biller, K. K. Miller, and A. Klibanski Growth Hormone Decreases Visceral Fat and Improves Cardiovascular Risk Markers in Women with Hypopituitarism: A Randomized, Placebo-Controlled Study J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2063 - 2071. [Abstract] [Full Text] [PDF]

				R. Ramakrishnan Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments J. Lipid Res., December 1, 2006; 47(12): 2738 - 2753. [Abstract] [Full Text] [PDF]

				E. R Christ, M. H Cummings, M. Stolinski, N. Jackson, P. J Lumb, A. S Wierzbicki, P. H Sonksen, D. L Russell-Jones, and A M. Umpleby Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study. Eur. J. Endocrinol., March 1, 2006; 154(3): 459 - 466. [Abstract] [Full Text] [PDF]

				M. Gola, S. Bonadonna, M. Doga, and A. Giustina Growth Hormone and Cardiovascular Risk Factors J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1864 - 1870. [Abstract] [Full Text] [PDF]

				P. Maison, S. Griffin, M. Nicoue-Beglah, N. Haddad, B. Balkau, and P. Chanson Impact of Growth Hormone (GH) Treatment on Cardiovascular Risk Factors in GH-Deficient Adults: A Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2192 - 2199. [Abstract] [Full Text] [PDF]

				E. R. Christ, M. H. Cummings, N. Jackson, M. Stolinski, P. J. Lumb, A. S. Wierzbicki, P. H. Sonksen, D. L. Russell-Jones, and A. M. Umpleby Effects of Growth Hormone (GH) Replacement Therapy on Low-Density Lipoprotein Apolipoprotein B100 Kinetics in Adult Patients with GH Deficiency: A Stable Isotope Study J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1801 - 1807. [Abstract] [Full Text] [PDF]

				S. Lind, M. Rudling, S. Ericsson, H. Olivecrona, M. Eriksson, B. Borgstrom, G. Eggertsen, L. Berglund, and B. Angelin Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 349 - 356. [Abstract] [Full Text]

				P. Maison and P. Chanson Cardiac Effects of Growth Hormone in Adults With Growth Hormone Deficiency: A Meta-Analysis Circulation, November 25, 2003; 108(21): 2648 - 2652. [Abstract] [Full Text] [PDF]

				C. Ameen and J. Oscarsson Sex Difference in Hepatic Microsomal Triglyceride Transfer Protein Expression Is Determined by the Growth Hormone Secretory Pattern in the Rat Endocrinology, September 1, 2003; 144(9): 3914 - 3921. [Abstract] [Full Text] [PDF]

				F. Frick, D. Linden, C. Ameen, S. Eden, A. Mode, and J. Oscarsson Interaction between growth hormone and insulin in the regulation of lipoprotein metabolism in the rat Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1023 - E1031. [Abstract] [Full Text] [PDF]

				T. Kearney, C. Navas de Gallegos, A. Chrisoulidou, R. Gray, P. Bannister, S. Venkatesan, and D. G. Johnston Hypopituitarsim Is Associated with Triglyceride Enrichment of Very Low-Density Lipoprotein J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3900 - 3906. [Abstract] [Full Text] [PDF]

				A. M. Thomas and L. Berglund Growth Hormone and Cardiovascular Disease: An Area in Rapid Growth J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1871 - 1873. [Full Text]

				D. Linden, A. Sjoberg, L. Asp, L. Carlsson, and J. Oscarsson Direct effects of growth hormone on production and secretion of apolipoprotein B from rat hepatocytes Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1335 - E1346. [Abstract] [Full Text] [PDF]

				J. A. M. Beentjes, A. van Tol, W. J. Sluiter, and R. P. F. Dullaart Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults J. Lipid Res., June 1, 2000; 41(6): 925 - 932. [Abstract] [Full Text]

				Discontinuation of Growth Hormone (GH) Treatment: Metabolic Effects in GH-Deficient and GH-Sufficient Adolescent Patients Compared with Control Subjects J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4516 - 4524. [Abstract] [Full Text]

				E. R. Christ, P. V. Carroll, E. Albany, A. M. Umpleby, P. J. Lumb, A. S. Wierzbicki, P. H. Sonksen, and D. L. Russell-Jones Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus Am J Physiol Endocrinol Metab, May 1, 2002; 282(5): E1154 - E1162. [Abstract] [Full Text] [PDF]